Level72 Asset Administration elevated stake in Tricida, Inc. By Investing.com
© Reuters. Point72 Asset Management increased stake in Tricida, Inc.
On March 23, Point72 Asset Management bought 1.3 million Tricida , Inc. (NASDAQ 🙂 shares priced at $ 6.6 million at an average price of $ 5.01 per share. Tricida, Inc. shares are down -5.39% since the transaction.
Point72 Asset Management’s stake in Tricida, Inc. increased to around 2.5 million shares with the purchase.
Point72 Asset Management first bought shares in Tricida, Inc. in the fourth quarter of 2018 Point72 Asset Management also owns AstraZeneca PLC ADR (NASDAQ :), Merck (MRK), Eli Lilly & Co (NYSE 🙂 and Chinook Therapeutics, Inc. (KDNY) . Tricida, Inc. ranks number thirty-nine among biotechnology and life science stocks by number of shares and market value.
Other investors who have also increased their Tricida, Inc. shares are Citigroup (NYSE 🙂 and Millennium Management. In contrast, the T. Rowe Price Equity Income Fund and Squarepoint Ops trimmed TCDA stocks.
Point72 Asset Management recently reduced its stake in VYNE Therapeutics INC (VYNE) and MacroGenics, Inc. (NASDAQ :). The total value of the shares sold is estimated at approximately $ 53 million.
In addition, Point72 Asset Management has made new investments in CytomX Therapeutics, Inc. (NASDAQ 🙂 and AnaptysBio, Inc. (NASDAQ :). Point72 Asset Management also increased its stake in Affimed NV (NASDAQ :), Kadmon Holdings Inc (NASDAQ :), Bicycle Therapeutics plc (NASDAQ 🙂 and Mereo BioPharma Group plc (MREO). The total value of the shares purchased is estimated at approximately $ 123 million.
Point72 Asset Management also reduced its stake in Syros Pharmaceuticals, Inc. (NASDAQ :), American Eagle Outfitter Inc (NYSE :), Childrens Place Inc (PLCE), Cytokinetics Inc (NASDAQ :), ANGI Homeservices Inc (NASDAQ :), Dave & Busters Entertainment Inc (NASDAQ :), Otonomy, Inc. (NASDAQ :), Calithera Biosciences, Inc. (CALA), Chiasma Inc. (NASDAQ 🙂 and Fulcrum Therapeutics, Inc. (NASDAQ :). The total value of the shares sold is estimated at approximately $ 58 million.
In addition, Point72 Asset Management has new investments in Curis Inc. (CRIS), Miragen Therapeutics Inc. (NASDAQ :), Aeglea BioTherapeutics Inc. (AGLE), Hims & Hers Health Inc. (HIMS) and Paya Holdings Inc. (PAYA) founded). Point72 Asset Management also increased its stake in Alliance data systems Corp (NYSE :), BioCryst (NASDAQ 🙂 Pharmaceuticals Inc (BCRX), BGC partner Inc (NASDAQ :), Rotate group Inc (NYSE 🙂 and Acorda Therapeutics Inc (NASDAQ :). The total value of the shares purchased is estimated at around $ 270 million.
Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. As a result, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any person involved with Fusion Media assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.